We’re pleased to announce our investment in Neurode’s $3.5m US seed round alongside Khosla Ventures and Psymed Ventures.ADHD is outpacing standard of care.Attention-deficit-hyperactive disorder (ADHD) is no longer just a quirk in childhood…
Why we invested in Neurode.We’re pleased to announce our investment in Neurode’s $3.5m US seed round alongside Khosla Ventures and Psymed Ventures.ADHD is outpacing standard of care.Attention-deficit-hyperactive disorder (ADHD) is no longer…
Harikesh Pushpapathan
https://stoicvc.com.au/wp-content/uploads/2024/10/1-s35x1qPMloQTfOLx3wT2Q.png2711024Harikesh Pushpapathanhttps://stoicvc.com.au/wp-content/uploads/2023/04/Screen-Shot-2023-04-25-at-5.44.30-pm-300x137.pngHarikesh Pushpapathan2024-10-06 06:11:222024-10-07 23:00:22Why we invested in Neurode
We’re pleased to announce our investment in Neurode’s $3.5m US seed round alongside Khosla Ventures and Psymed Ventures.ADHD is outpacing standard of care.Attention-deficit-hyperactive disorder (ADHD) is no longer just a quirk in childhood…
Harikesh Pushpapathan
https://stoicvc.com.au/wp-content/uploads/2024/10/15zYQymd2N-wcjojmIfdMOw.jpeg6831024Harikesh Pushpapathanhttps://stoicvc.com.au/wp-content/uploads/2023/04/Screen-Shot-2023-04-25-at-5.44.30-pm-300x137.pngHarikesh Pushpapathan2024-10-06 06:11:222025-02-08 19:30:19Why we invested in Neurode.
